Time-Limited Pirtobrutinib-Based Triplet Yields High Rates of Undetectable MRD in First-Line CLL

The phase 2 PIVOT-CLL trial demonstrated that a time-limited triplet therapy of pirtobrutinib, venetoclax, and obinutuzumab achieved high rates of undetectable measurable residual disease (U-MRD) and excellent 2-year survival rates in treatment-naive chronic lymphocytic leukemia (CLL) patients, with most patients able to stop therapy after one year.

This Wire brief sits within Fusion42's coverage of Biotech.